Showing 1 to 10 of 1,959
| Title | Reference number | Reference number sort | Published | Published date sort | Last updated | Last updated sort |
|---|---|---|---|---|---|---|
| COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 | Reference number:ES24 | ES00024 | Published:21 May 2020 | 20200521 | Last updated:21 May 2020 | 20200521 |
| COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 | Reference number:ES25 | ES00025 | Published:21 May 2020 | 20200521 | Last updated:21 May 2020 | 20200521 |
| COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis | Reference number:ES26 | ES00026 | Published:21 May 2020 | 20200521 | Last updated:21 May 2020 | 20200521 |
| Cytokine adsorption devices for treating respiratory failure in people with COVID-19 | Reference number:MIB217 | MIB00217 | Published:21 May 2020 | 20200521 | Last updated:21 May 2020 | 20200521 |
| COVID-19 rapid guideline: children and young people who are immunocompromised | Reference number:NG174 | NG00174 | Published:01 May 2020 | 20200501 | Last updated:21 May 2020 | 20200521 |
| COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders | Reference number:NG167 | NG00167 | Published:03 April 2020 | 20200403 | Last updated:21 May 2020 | 20200521 |
| COVID-19 rapid guideline: dialysis service delivery | Reference number:NG160 | NG00160 | Published:20 March 2020 | 20200320 | Last updated:21 May 2020 | 20200521 |
| COVID-19 rapid guideline: chronic kidney disease | Reference number:NG176 | NG00176 | Published:15 May 2020 | 20200515 | Last updated:15 May 2020 | 20200515 |
| COVID-19 rapid guideline: interstitial lung disease | Reference number:NG177 | NG00177 | Published:15 May 2020 | 20200515 | Last updated:15 May 2020 | 20200515 |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | Reference number:TA628 | TA00628 | Published:13 May 2020 | 20200513 | Last updated:13 May 2020 | 20200513 |